- Home
- PHAT vs KOD Comparison
PHAT vs KOD Comparison
Compare PHAT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- KOD
- Stock Information
- Founded
- PHAT 2018
- KOD 2009
- Country
- PHAT United States
- KOD United States
- Employees
- PHAT N/A
- KOD N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHAT Health Care
- KOD Health Care
- Exchange
- PHAT Nasdaq
- KOD Nasdaq
- Market Cap
- PHAT 465.0M
- KOD 454.7M
- IPO Year
- PHAT 2019
- KOD 2018
- Fundamental
- Price
- PHAT $6.96
- KOD $7.17
- Analyst Decision
- PHAT Strong Buy
- KOD Hold
- Analyst Count
- PHAT 4
- KOD 4
- Target Price
- PHAT $23.00
- KOD $8.00
- AVG Volume (30 Days)
- PHAT 971.9K
- KOD 464.9K
- Earning Date
- PHAT 03-06-2025
- KOD 11-14-2024
- Dividend Yield
- PHAT N/A
- KOD N/A
- EPS Growth
- PHAT N/A
- KOD N/A
- EPS
- PHAT N/A
- KOD N/A
- Revenue
- PHAT $26,270,000.00
- KOD N/A
- Revenue This Year
- PHAT $7,622.43
- KOD N/A
- Revenue Next Year
- PHAT $236.87
- KOD N/A
- P/E Ratio
- PHAT N/A
- KOD N/A
- Revenue Growth
- PHAT N/A
- KOD N/A
- 52 Week Low
- PHAT $6.07
- KOD $2.19
- 52 Week High
- PHAT $19.71
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- PHAT 37.02
- KOD 42.02
- Support Level
- PHAT $6.36
- KOD $7.21
- Resistance Level
- PHAT $7.20
- KOD $9.14
- Average True Range (ATR)
- PHAT 0.48
- KOD 0.89
- MACD
- PHAT 0.08
- KOD -0.35
- Stochastic Oscillator
- PHAT 30.48
- KOD 0.27
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.